局限期原发性食管小细胞癌的治疗策略

doi:10.3969/j.issn.1006-5725.2025.11.001

Abstract

Abstract:

Primary small cell carcinoma of esophagus （PSCCE） is a rare and highly aggressive neuroendocrine tumor， accounting for 0.05% to 3.1% of all esophageal malignancies. Its biological characteristics are similar to those of small cell lung cancer， with highly aggressive behavior and early dissemination tendency. It often metastasizes rapidly through lymphatic and hematogenous pathways.The prognosis is extremely poor， with a 5-year overall survival rate of less than 15%. There are no large-scale randomized controlled trials， and no standard treatment strategies have been established. In recent years， the treatment of limited-stage PSCCE has become a focal point of research. In traditional treatment paradigms， endoscopic therapy is feasible for very early-stage cases， while radical surgery serves as the primary approach for relatively early-stage patients. For locally advanced cases， two predominant treatment modalities are commonly employed in clinical practice： a surgery-based comprehensive treatment regimen and a radical chemoradiotherapy-centered therapeutic protocol， with no definitive conclusion yet reached regarding the optimal treatment strategy. Concurrently， emerging therapeutic strategies such as immunotherapy and molecularly targeted therapy have demonstrated remarkable clinical efficacy， thereby providing novel therapeutic opportunities for limited-stage PSCCE. This article aims to review the recent advances in the treatment of limited-stage PSCCE， summarize the current diagnostic and therapeutic landscape， and outline future directions in this field.

Key words: small cell carcinoma, esophageal carcinoma, treatment, survival

CLC Number:

R735.1

Xiaolin QIU,Bingjie FAN,Linlin WANG. Treatment strategies for limited⁃stage primary small cell carcinoma of esophagus[J]. The Journal of Practical Medicine, 2025, 41(11): 1603-1610.

References 58

1	JEENE P M， GEIJSEN E D， MUIJS C T， et al. Small Cell Carcinoma of the Esophagus： A Nationwide Analysis of Treatment and Outcome at Patient Level in Locoregional Disease ［J］. Am J Clin Oncol， 2019， 42（6）： 534-538. doi:10.1097/coc.0000000000000546 doi: 10.1097/coc.0000000000000546
2	LIU D， WU D， NI J， et al. NSE and ProGRP Are Promising Markers for Diagnosis， Efficacy Evaluation， Follow-Up Monitoring， and Prognosis of Small Cell Esophageal Carcinoma ［J］. Thorac Cancer， 2025， 16（4）： e70026. doi:10.1111/1759-7714.70026 doi: 10.1111/1759-7714.70026
3	ISHIDA H， KASAJIMA A， ONODERA Y， et al. A comparative analysis of clinicopathological factors between esophageal small cell and basaloid squamous cell carcinoma ［J］. Medicine （Baltimore）， 2019， 98（8）： e14363. doi:10.1097/md.0000000000014363 doi: 10.1097/md.0000000000014363
4	PANDA G S， NORONHA V， YADAV S， et al. Small cell carcinoma of the oesophagus： Experience of an Indian Tertiary Cancer Centre ［J］. Ecancermedicalscience， 2022， 16：1393. doi:10.3332/ecancer.2022.1393 doi: 10.3332/ecancer.2022.1393
5	LI T， CHEN S， ZHANG Z， et al. Chemotherapy Plus Radiotherapy Versus Radiotherapy in Patients With Small Cell Carcinoma of the Esophagus： A SEER Database Analysis ［J］. Cancer Control， 2021， 28：1073274821989321. doi:10.1177/1073274821989321 doi: 10.1177/1073274821989321
6	AIJAZ P， NIAZI M A， CHELA H K， et al. Epigastric Pain and Dysphagia in a 36-Year-Old Man Due to Primary Esophageal Small Cell Carcinoma ［J］. Am J Case Rep， 2024， 25：e943392. doi:10.12659/ajcr.943392 doi: 10.12659/ajcr.943392
7	HOSSEINI S， SALEK R， NASROLAHI H， et al. Small Cell Carcinoma of the Esophagus： Clinicopathological Features and Outcome of 22 Cases ［J］. Iran Red Crescent Med J， 2015， 17（11）： e20353. doi:10.5812/ircmj.20353 doi: 10.5812/ircmj.20353
8	WALENKAMP A M， SONKE G S， SLEIJFER D T. Clinical and therapeutic aspects of extrapulmonary small cell carcinoma ［J］. Cancer Treat Rev， 2009， 35（3）： 228-236. doi:10.1016/j.ctrv.2008.10.007 doi: 10.1016/j.ctrv.2008.10.007
9	FRAZIER S R， KAPLAN P A， LOY T S. The pathology of extrapulmonary small cell carcinoma ［J］. Semin Oncol， 2007， 34（1）： 30-38. doi:10.1053/j.seminoncol.2006.11.017 doi: 10.1053/j.seminoncol.2006.11.017
10	RICE T W， ISHWARAN H， FERGUSON M K， et al. Cancer of the Esophagus and Esophagogastric Junction： An Eighth Edition Staging Primer ［J］. J Thorac Oncol， 2017， 12（1）： 36-42. doi:10.1016/j.jtho.2016.10.016 doi: 10.1016/j.jtho.2016.10.016
11	MIAO H， LI R， CHEN D， et al. Survival outcomes and prognostic factors of primary small cell carcinoma of the esophagus ［J］. J Thorac Dis， 2021， 13（5）： 2790-2802. doi:10.21037/jtd-20-3334 doi: 10.21037/jtd-20-3334
12	WANG H H， ZAORSKY N G， MENG M B， et al. Multimodality therapy is recommended for limited-stage combined small cell esophageal carcinoma ［J］. Onco Targets Ther， 2015， 8：437-444. doi:10.2147/ott.s76048 doi: 10.2147/ott.s76048
13	XIE M R， XU S B， SUN X H， et al. Role of surgery in the management and prognosis of limited-stage small cell carcinoma of the esophagus ［J］. Dis Esophagus， 2015， 28（5）： 476-482. doi:10.1111/dote.12230 doi: 10.1111/dote.12230
14	SONG Y， WANG W， TAO G， et al. Survival benefit of radiotherapy to patients with small cell esophagus carcinoma： an analysis of Surveillance Epidemiology and End Results （SEER） data ［J］. Oncotarget， 2016， 7（13）： 15474-15480. doi:10.18632/oncotarget.6764 doi: 10.18632/oncotarget.6764
15	XU L， LI Y， LIU X， et al. Treatment Strategies and Prognostic Factors of Limited-Stage Primary Small Cell Carcinoma of the Esophagus ［J］. J Thorac Oncol， 2017， 12（12）： 1834-1844. doi:10.1016/j.jtho.2017.09.1966 doi: 10.1016/j.jtho.2017.09.1966
16	ZHAO K， HUANG Z， SI Y， et al. Use of Chemoradiotherapy as a Treatment Option for Patients with Limited-Stage Primary Small Cell Carcinoma of the Esophagus ［J］. Cancer Manag Res， 2021， 13：613-623. doi:10.2147/cmar.s278914 doi: 10.2147/cmar.s278914
17	ZHU J， WANG Y， SUN H， et al. Surgery versus radiotherapy for limited-stage small cell esophageal carcinoma： a multicenter， retrospective， cohort study in China （ChiSCEC）［J］. Int J Surg， 2024， 110（2）： 956-964. doi:10.1097/JS9.0000000000000912 doi: 10.1097/JS9.0000000000000912
18	ZEMERLY S， THURAIRAJASINGAM K， DEEB B， et al. Small Cell Oesophageal Carcinoma： A Retrospective Case Series From a UK Tertiary Centre and a Review of the Literature ［J］. Cureus， 2023， 15（11）： e49435. doi:10.7759/cureus.49435 doi: 10.7759/cureus.49435
19	ZHU J， LIANG X， CHEN S， et al. Endoscopic therapy versus esophagectomy for T1bN0M0 esophageal cancer： A population-based study using propensity score matching ［J］. Heliyon， 2023， 9（11）： e22189. doi:10.1016/j.heliyon.2023.e22189 doi: 10.1016/j.heliyon.2023.e22189
20	YANG X， MEN Y， WANG J， et al. Additional Radiotherapy With or Without Chemotherapy Following Endoscopic Resection for Stage I Esophageal Carcinoma： A Pilot Study ［J］. Technol Cancer Res Treat， 2021， 20：15330338211048051. doi:10.1177/15330338211048051 doi: 10.1177/15330338211048051
21	CHEN W W， WANG F， CHEN S， et al. Detailed analysis of prognostic factors in primary esophageal small cell carcinoma ［J］. Ann Thorac Surg， 2014， 97（6）： 1975-1981. doi:10.1016/j.athoracsur.2014.02.037 doi: 10.1016/j.athoracsur.2014.02.037
22	ZOU B， LI T， ZHOU Q， et al. Adjuvant Therapeutic Modalities in Primary Small Cell Carcinoma of Esophagus Patients： A Retrospective Cohort Study of Multicenter Clinical Outcomes ［J］. Medicine （Baltimore）， 2016， 95（17）： e3507. doi:10.1097/md.0000000000003507 doi: 10.1097/md.0000000000003507
23	FAN N， WANG Z， HUANG Y， et al. A Retrospective Study of 52 Patients With Primary Small Cell Carcinoma of the Esophagus Treated With Radical Surgery ［J］. Cancer Control， 2021， 28：10732748211027147. doi:10.1177/10732748211027147 doi: 10.1177/10732748211027147
24	CAI G， WANG J， ZOU B， et al. Preoperative Chemotherapy for Limited-stage Small Cell Carcinoma of the Esophagus ［J］. Ann Thorac Surg， 2022， 114（4）： 1220-1228. doi:10.1016/j.athoracsur.2021.08.059 doi: 10.1016/j.athoracsur.2021.08.059
25	YAN H， ZHU H， CAI Y， et al. Treatment strategies for limited-stage small cell carcinoma of the esophagus： Evidence from a Chinese multicenter cohort study and the American SEER database ［J］. J Thorac Dis， 2024， 16（11）： 7787-7796. doi:10.21037/jtd-24-1394 doi: 10.21037/jtd-24-1394
26	WU J， XIA X， GONG L， et al. Neoadjuvant chemoimmunotherapy for small cell carcinoma of the esophagus： Clinical efficacy and biomarker exploration ［J］. Hum Vaccin Immunother， 2024， 20（1）： 2370085. doi:10.1080/21645515.2024.2370085 doi: 10.1080/21645515.2024.2370085
27	QIN J， XUE L， HAO A， et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma： The randomized phase 3 ESCORT-NEO/NCCES01 trial ［J］. Nat Med， 2024， 30（9）： 2549-2557. doi:10.1038/s41591-024-03064-w doi: 10.1038/s41591-024-03064-w
28	LI C， ZHAO S， ZHENG Y， et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma （PALACE-1）［J］. Eur J Cancer， 2021， 144：232-241. doi:10.1016/j.ejca.2020.11.039 doi: 10.1016/j.ejca.2020.11.039
29	LIU J， YANG Y， LIU Z， et al. Multicenter， single-arm， phase Ⅱ trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma ［J］. J Immunother Cancer， 2022， 10（3）： e004291. doi:10.1136/jitc-2021-004291corr1 doi: 10.1136/jitc-2021-004291corr1
30	CHENG J， GUO M， YANG Y， et al. Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma ［J］. Front Immunol， 2022， 13：848881. doi:10.3389/fimmu.2022.848881 doi: 10.3389/fimmu.2022.848881
31	XIAO Q， XIAO H， OUYANG S， et al. Primary small cell carcinoma of the esophagus： Comparison between a Chinese cohort and Surveillance， Epidemiology， and End Results （SEER） data ［J］. Cancer Med， 2019， 8（3）： 1074-1085. doi:10.1002/cam4.2001 doi: 10.1002/cam4.2001
32	JEENE P M， GEIJSEN E D， MUIJS C T， et al. Small Cell Carcinoma of the Esophagus： A Nationwide Analysis of Treatment and Outcome at Patient Level in Locoregional Disease ［J］. Am J Clin Oncol， 2019， 42（6）： 534-538. doi:10.1097/coc.0000000000000546 doi: 10.1097/coc.0000000000000546
33	LI R， YANG Z， SHAO F， et al. Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypes ［J］. Nat Commun， 2021， 12（1）： 3785. doi:10.1038/s41467-021-24043-6 doi: 10.1038/s41467-021-24043-6
34	VERMA V， SLEIGHTHOLM R L， FANG P， et al. National Cancer Database report of nonmetastatic esophageal small cell carcinoma ［J］. Cancer Med， 2018， 7（12）： 6365-6373. doi:10.1002/cam4.1712 doi: 10.1002/cam4.1712
35	WONG A T， SHAO M， RINEER J， et al. Treatment and survival outcomes of small cell carcinoma of the esophagus： an analysis of the National Cancer Data Base ［J］. Dis Esophagus， 2017， 30（2）： 1-5.
36	MENG M B， ZAORSKY N G， JIANG C， et al. Radiotherapy and chemotherapy are associated with improved outcomes over surgery and chemotherapy in the management of limited-stage small cell esophageal carcinoma ［J］. Radiother Oncol， 2013， 106（3）： 317-322. doi:10.1016/j.radonc.2013.01.008 doi: 10.1016/j.radonc.2013.01.008
37	DING J， JI J， ZHU W， et al. A retrospective study of different treatments of limited-stage small-cell esophageal carcinoma and associated prognostic factor analysis ［J］. Dis Esophagus， 2013， 26（7）： 696-702. doi:10.1111/dote.12017 doi: 10.1111/dote.12017
38	GAO R， ZHANG Y， WEN X P， et al. Chemotherapy with cisplatin or carboplatin in combination with etoposide for small-cell esophageal cancer： a systemic analysis of case series ［J］. Dis Esophagus， 2014， 27（8）： 764-769. doi:10.1111/dote.12149 doi: 10.1111/dote.12149
39	郝雁冰，王丽，容宇，等. 3种化疗方案用于小细胞食管癌的疗效和安全性比较［J］. 中国药房， 2017， 28（12）： 1623-1625. doi:10.6039/j.issn.1001-0408.2017.12.12 doi: 10.6039/j.issn.1001-0408.2017.12.12
40	SHAPIRO J， VAN LANSCHOT J J B， HULSHOF M， et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer （CROSS）： long-term results of a randomised controlled trial ［J］. Lancet Oncol， 2015， 16（9）： 1090-1098. doi:10.1016/S1470-2045(15)00040-6 doi: 10.1016/S1470-2045(15)00040-6
41	YAN X， DUAN H， NI Y， et al. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer： A prospective， single-arm， phase II study （TD-NICE）［J］. Int J Surg， 2022， 103：106680. doi:10.1097/js9.0000000000000292 doi: 10.1097/js9.0000000000000292
42	HERMANN R M， CHRISTIANSEN H. A new standard is emerging： PD-1 maintenance therapy after neoadjuvant radiochemotherapy and curative resection of oesophageal and AEG carcinomas （CheckMate 577）［J］. Strahlenther Onkol， 2021， 197（11）： 1040-1042. doi:10.1007/s00066-021-01849-3 doi: 10.1007/s00066-021-01849-3
43	ZHAO Q， CHEN Y X， WU Q N， et al. Systematic analysis of the transcriptome in small-cell carcinoma of the oesophagus reveals its immune microenvironment ［J］. Clin Transl Immunology， 2020， 9（10）： e1173. doi:10.1002/cti2.1173 doi: 10.1002/cti2.1173
44	ZHAO K， MA L， FENG L， et al. CD155 Overexpression Correlates With Poor Prognosis in Primary Small Cell Carcinoma of the Esophagus ［J］. Front Mol Biosci， 2020， 7：608404. doi:10.3389/fmolb.2020.608404 doi: 10.3389/fmolb.2020.608404
45	YAMASHITA S， ABE H， YAMASHITA H， et al. PD-L1 and HLA-class I expression status and their therapeutic implication in oesophageal small-cell carcinoma ［J］. Histopathol， 2023， 83（2）： 264-275. doi:10.1111/his.14924 doi: 10.1111/his.14924
46	ZHANG C， ZHANG G， XUE L， et al. Patterns and prognostic values of programmed cell death-ligand 1 expression and CD8 + T-cell infiltration in small cell carcinoma of the esophagus： a retrospective analysis of 34 years of National Cancer Center data in China ［J］. Int J Surg， 2024， 110（7）： 4297-4309. doi:10.1097/js9.0000000000000064 doi: 10.1097/js9.0000000000000064
47	SENAN S， OKAMOTO I， LEE G W， et al. Design and Rationale for a Phase Ⅲ， Randomized， Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer： The ADRIATIC Study ［J］. Clin Lung Cancer， 2020， 21（2）： e84-e88. doi:10.1016/j.cllc.2019.12.006 doi: 10.1016/j.cllc.2019.12.006
48	SHAH M A， BENNOUNA J， DOI T， et al. KEYNOTE-975 study design： a Phase Ⅲ study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma ［J］. Future Oncol， 2021， 17（10）： 1143-1153. doi:10.2217/fon-2020-0969 doi: 10.2217/fon-2020-0969
49	SUN J， GAN W， YAO J， et al. Peripheral blood lymphocyte subpopulations as predictive biomarkers for first-line programmed death 1 inhibitors efficacy in esophageal squamous cell carcinoma： A retrospective study ［J］. Medicine （Baltimore）， 2024， 103（40）： e39967. doi:10.1097/MD.0000000000039967 doi: 10.1097/MD.0000000000039967
50	CHEN W， CAO K， ZHANG L， et al. Efficacy and safety evaluation of frontline immunotherapy combinations in advanced esophageal squamous cell carcinoma： A network meta-analysis highlighting the value of PD-L1 expression positivity scores ［J］. Front Immunol， 2024， 15：1414753. doi:10.3389/fimmu.2024.1414753 doi: 10.3389/fimmu.2024.1414753
51	王豪，陆筱祎，王文杰. 老年局部晚期食管癌同步放化疗序贯信迪利单抗免疫治疗的疗效［J］. 实用医学杂志， 2025， 41（3）： 365-370.
52	REN W， WU P， TIAN J， et al. Anti-PD-1 therapy plus chemotherapy showed superior and durable survival benefit in a patient with small cell esophageal cancer： A case report ［J］. Thorac Cancer， 2021， 12（2）： 264-267. doi:10.1111/1759-7714.13735 doi: 10.1111/1759-7714.13735
53	ISHIDA H， KASAJIMA A， KAMEI T， et al. SOX2 and Rb1 in esophageal small-cell carcinoma： Their possible involvement in pathogenesis ［J］. Mod Pathol， 2017， 30（5）： 660-671. doi:10.1038/modpathol.2016.222 doi: 10.1038/modpathol.2016.222
54	WANG F， LIU D B， ZHAO Q， et al. The genomic landscape of small cell carcinoma of the esophagus ［J］. Cell Res， 2018， 28（7）： 771-774. doi:10.1038/s41422-018-0039-1 doi: 10.1038/s41422-018-0039-1
55	ZHU M， CHU Y， YUAN Q， et al. Integrated bioinformatics analysis to explore potential therapeutic targets and drugs for small cell carcinoma of the esophagus ［J］. Front Bioinform， 2025， 5：1495052. doi:10.3389/fbinf.2025.1495052 doi: 10.3389/fbinf.2025.1495052
56	周乾华，毕华俊，孟凡东，等. miR-30b-5p通过下调MKRN3表达抑制食管癌细胞增殖、迁移和侵袭［J］. 实用医学杂志， 2023， 39（13）： 1627-1633.
57	ZHANG C， YU G M， ZHANG M， et al. S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus： A case report and review of the literature ［J］. Medicine （Baltimore）， 2020， 99（3）： e18892. doi:10.1097/md.0000000000018691 doi: 10.1097/md.0000000000018691
58	WANG W， ZHANG X， FANG Y， et al. Case Report： Olaparib Shows Satisfactory Clinical Outcomes Against Small Cell Esophageal Carcinoma With ATM Mutation ［J］. Front Oncol， 2022， 12：808801. doi:10.3389/fonc.2022.808801 doi: 10.3389/fonc.2022.808801

[1]	Tong LIU,Yan ZHANG,Haoyu WANG,Mengzhen WANG,Shengjie LING,Yiming. ZHANG. Analysis of retreatment and influencing factors in patients with endometrial cancer and atypical endometrial hyperplasia after fertility⁃preserving treatment recurrence [J]. The Journal of Practical Medicine, 2025, 41(8): 1259-1266.
[2]	Huiling YE,Zhengchaoyi CHEN,Yihan HUANG,Yingjie ZHANG,Xiangbin ZHANG,Yuehu PU,Renming ZHONG. Radiotherapy treatment comparison of liver SBRT between 4D⁃CT and deep inspiration breath hold troughmagnetic resonance imaging [J]. The Journal of Practical Medicine, 2025, 41(7): 1044-1049.
[3]	Yingding ZHAO,Bangsheng LI,Tiantian XUE,Qihan ZI,Xin YANG,Xi WANG. Efficacy and complications of microwave ablation and sublobectomy for treating ⅠA⁃stage NSCLC： A comparative analysis based on propensity score matching [J]. The Journal of Practical Medicine, 2025, 41(7): 976-984.
[4]	Hexue YUAN,Feng TIAN,Hui LI,Fang LUO,Liang ZHAO,Zongjian LIU,Chunlai PAN,Lijun LIU,Na. ZHU. Clinical efficacy of surgical treatment combined with IFX and UST on Crohn′s anal fistulae [J]. The Journal of Practical Medicine, 2025, 41(6): 872-876.
[5]	Yang HUANG,Ge QU,Peizong WANG,Weian ZENG,Fang. YAN. Association between intraoperative dexamethasone and long-term survival in non-small cell lung cancer patients undergoing curative resection [J]. The Journal of Practical Medicine, 2025, 41(5): 724-730.
[6]	Wei WANG,Shihua LU,Honghao ZHANG,Hualiang. DENG. Research progress on mechanism of paeonol in the treatment of intestinal diseases [J]. The Journal of Practical Medicine, 2025, 41(10): 1597-1602.
[7]	Tingting HU,Hongling LU,Xiaoming YIN,Qian LIU,Wei GUO,Yunchuan SUN. Evaluate value of serum PLOD3 and CYFRA21⁃1 on the efficacy of three⁃dimensional brachytherapy in patients with lung metastases [J]. The Journal of Practical Medicine, 2025, 41(1): 120-125.
[8]	Shuanghao ZHANG,Jie TAO,Zehua CAI,Xuerong RAN,Sisi WEI,Jinfeng PAN,Jinguo ZHAI. A study of the current status of female pelvic floor dysfunction patients′ knowledge of minimally invasive laser treatment of the reproductive tract and their intention to make treatment decisions [J]. The Journal of Practical Medicine, 2025, 41(1): 126-133.
[9]	Qiaofang HUANG,Xingxiao HUANG,Junyi LIN,Lian DUAN,Zhentai PANG,Shaojuan WU,Caimei ZOU,Shichao XU. Effect of physician⁃nurse⁃social worker linkage rehabilitation model on psychological status in patients receiving methadone maintenance treatment [J]. The Journal of Practical Medicine, 2024, 40(9): 1238-1243.
[10]	Tianyue CUI,Liquan OUYANG,Shengchu. ZHANG. Clinical efficacy of simple surgery and surgery combined with glucocorticoids in the treatment of mass type granulomatous mastitis [J]. The Journal of Practical Medicine, 2024, 40(9): 1268-1274.
[11]	Shuangyan LI,Bin ZHANG. Research status and challenges of insomnia disorder [J]. The Journal of Practical Medicine, 2024, 40(6): 731-737.
[12]	Yuxin CHENG,Liang LIU,Shiyu DONG,Shengchao LI,Meng ZHANG. Research advances in exosomal proteins， mRNA and non⁃coding RNA regulation of Hepatocellular Carcinoma [J]. The Journal of Practical Medicine, 2024, 40(6): 748-755.
[13]	Pengshuai SUN,Feng ZHU,Lihong ZHENG,Haiqiang WANG. Research progress in the treatment of AMPK regulating lipid accumulation in the treatment of nonalcoholic fatty liver disease [J]. The Journal of Practical Medicine, 2024, 40(6): 862-866.
[14]	Guangping WU,Xin YIN,Jianzhuo HE,Liheng. GUO. The effect of Xinmailong injection on microcirculation in patients with septic shock [J]. The Journal of Practical Medicine, 2024, 40(5): 627-631.
[15]	Rui XU,Xingbing. HUANG. Progress of non-pharmacological treatments for treatment-resistant depression [J]. The Journal of Practical Medicine, 2024, 40(4): 439-446.

Treatment strategies for limited⁃stage primary small cell carcinoma of esophagus

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 58

Related Articles 15

Recommended Articles

Metrics

Comments